Predictors of outcome in XXXX with @entity1906 .

@entity1 @entity129 @entity410 @entity40489 @entity1032 @entity1158 @entity233 @entity16 @entity772 @entity51 @entity1906 @entity63096 @entity3122 @entity33470 @entity378
OBJECTIVE: To assess predictors of mortality and @entity16 in @entity1 with @entity1906 ( @entity1906 ). METHODS: @entity1 with @entity1906 treated at 12 university hospitals in @entity233 between 1985 and 1997 were evaluated using a standardised protocol applied retrospectively. Variables associated with hospital mortality as well as with the presence of @entity16 at 6 months were determined using logistic regression models. RESULTS: Four hundred and thirty-four @entity1 between the ages of 13 and 83 years (mean 33 years) were evaluated. Sixty-eight per cent of these @entity1 presented with Medical Research Council Stage II or III. One hundred and one @entity1 (23.3%) died and 67 (27%) of evaluable survivors had @entity16 . In multi-variable analysis, @entity410 ( @entity40489 , 95%CI 1.2-9.0, P = 0.02), @entity1032 (OR 6.0, 95%CI 3.6-10.2, P = 0.01), and delayed or interrupted treatment (OR 5.1, 95%CI 2.4-11.2, P = 0.01) were shown to be predictors for mortality. The presence of @entity1906 ( @entity3122 , 95%CI 1.1-4.2, P = 0.035), @entity129 (OR 2.6, 95%CI 1.4-4.2, P = 0.01), hemiparesia/focal weakness ( @entity63096 , 95%CI 3.8-22.6, P = 0.01), @entity1158 /multiple @entity51 ( @entity33470 , 95%CI 2.14-23.38, P = 0.01) and drowsiness (OR 4.2, 95%CI 2.04-8.82, P = 0.01) were independent predictors of @entity16 at 6 months following hospital discharge. CONCLUSION: The results of this study emphasise the importance of prompt and uninterrupted anti- @entity378 therapy for @entity1906 . The presence of @entity410 or @entity772 on admission to hospital are important predictors for mortality, while the presence of focal neurological signs is a predictor for persistent @entity16 in survivors.
